CClinicalTrials.gg
CompletedNCT05209828Updated Apr 5, 2024

Post-market Clinical Follow-up of Pfmmedical Ports

An observational study in Vascular Access Port and Patient Satisfaction, sponsored by pfm medical gmbh. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-05.

Sponsored by pfm medical gmbh · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
149
Ages
18 Years and older
Sex
All
01

Study summary

Prospective, monocentric, non-randomised, observational post-market clinical follow-up study in Germany to obtain post-market information on the pfmmedical ports with a follow-up (FU) of 6 months. The focus is on patient reported satisfaction, clinical application, and complication rates.

02

Conditions studied

  • Vascular Access Port
  • Patient Satisfaction
03

In context

Lead sponsor

pfm medical gmbh is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

150 patients requiring repeated vascular access

Inclusion criteria

  • Age: ≥ 18 years.
  • Medical indication for port catheter implantation.
  • The patient is mentally able to understand the nature, aims and possible consequences of the PMCF study.
  • Patient information has been provided and written consent exists.

Exclusion criteria

Exclusion Criteria:

  • Contraindications according to the manufacturer´s instructions for use (IFU).
  • The patient is institutionalised by court or official order (MPDG §27).
  • Patient participates in another operative clinical investigation if it relates to the area of port devices and/or influences the primary endpoint of the PMCF study.
  • Patients who currently already have a port implanted.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
149 participants (actual)
Patient registry
No

Groups and cohorts

  • pfmmedical port implantation

    Port implantation for continous vascular access.

    Device: pfmmedical implantable vascular access ports

Interventions

  • Devicepfmmedical implantable vascular access ports

    Implantion of an implantable vascular access port which facilitates repeated vascular access intended for the delivery of medications, intravenous fluids, parenteral nutrition solutions or blood products and blood sampling using a Huber needle.

    Also known as: Jet Port® Plus II Contrast, T-Port Contrast, T-Port Low Profile Contrast

06

What researchers measure

Primary outcomes

  1. Patients satisfaction

    The study hypothesis is that the patients' satisfaction after the study intervention is not worse than the satisfaction identified in the current literature. Satisfaction is determined using the patient questionnaire (6 months after implantation). The following 4 domains of the validated questionnaire by Nagel et.al., 2012 are considered as relevant for the clinical outcome: * Overall, how satisfied are you with the port system? * In a similar situation, would you choose the port again? * How satisfied are you with the cosmetic result? * Does the port cause pain?

    Time frame: 6 months after port implantation

07

Study locations

1 site
  • Heidelberg University Hospital
    Heidelberg, Baden-Württemberg 69120, Germany
08

References and documents

Publications

  • Nagel SN, Teichgraber UK, Kausche S, Lehmann A. Satisfaction and quality of life: a survey-based assessment in patients with a totally implantable venous port system. Eur J Cancer Care (Engl). 2012 Mar;21(2):197-204. doi: 10.1111/j.1365-2354.2011.01275.x. Epub 2011 Aug 18. PubMed 21851433 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05209828
Lead sponsor
pfm medical gmbh
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Apr 13, 2022
Primary completion
Mar 9, 2023
Completion
Mar 9, 2023
Last update
Apr 5, 2024

Study contacts

Phillip Knebel, Prof. Dr.
principal investigator · University Hospital Heidelberg

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion